NZ527201A - Stable norastemizole formulations comprising coated norastemizole particles - Google Patents

Stable norastemizole formulations comprising coated norastemizole particles

Info

Publication number
NZ527201A
NZ527201A NZ527201A NZ52720198A NZ527201A NZ 527201 A NZ527201 A NZ 527201A NZ 527201 A NZ527201 A NZ 527201A NZ 52720198 A NZ52720198 A NZ 52720198A NZ 527201 A NZ527201 A NZ 527201A
Authority
NZ
New Zealand
Prior art keywords
norastemizole
particles
coated
stable
formulations
Prior art date
Application number
NZ527201A
Other languages
English (en)
Inventor
Martin P Redmon
Hal T Butler
Stephen A Wald
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of NZ527201A publication Critical patent/NZ527201A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ527201A 1997-03-26 1998-03-25 Stable norastemizole formulations comprising coated norastemizole particles NZ527201A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82447797A 1997-03-26 1997-03-26
US85178697A 1997-05-06 1997-05-06

Publications (1)

Publication Number Publication Date
NZ527201A true NZ527201A (en) 2004-12-24

Family

ID=27124816

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ52720098A NZ527200A (en) 1997-03-26 1998-03-25 Stable norastemizole formulations including a super disintegrant
NZ517472A NZ517472A (en) 1997-03-26 1998-03-25 Lactose free norastemizole formulations with improved stability
NZ527201A NZ527201A (en) 1997-03-26 1998-03-25 Stable norastemizole formulations comprising coated norastemizole particles

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NZ52720098A NZ527200A (en) 1997-03-26 1998-03-25 Stable norastemizole formulations including a super disintegrant
NZ517472A NZ517472A (en) 1997-03-26 1998-03-25 Lactose free norastemizole formulations with improved stability

Country Status (13)

Country Link
EP (1) EP1035869A1 (xx)
JP (1) JP2002512614A (xx)
KR (1) KR20010005746A (xx)
CN (1) CN1257431A (xx)
AR (1) AR012187A1 (xx)
BR (1) BR9808428A (xx)
CA (1) CA2284705A1 (xx)
HU (1) HUP0001823A3 (xx)
NO (1) NO994655L (xx)
NZ (3) NZ527200A (xx)
RU (1) RU2214245C2 (xx)
WO (1) WO1998042379A2 (xx)
ZA (1) ZA982562B (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ289261B6 (cs) * 2000-07-11 2001-12-12 Léčiva, A.S. Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby
EP2201982A1 (en) * 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
EP2496217B1 (en) * 2009-08-24 2019-03-27 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Direct compression tablets of otilonium

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0232937B1 (en) * 1986-02-03 1992-08-19 Janssen Pharmaceutica N.V. Anti-histaminic compositions containing n-heterocyclyl-4-piperidinamines
DE4037426A1 (de) * 1990-11-24 1992-05-27 Kali Chemie Pharma Gmbh Piperidinoalkylbenzoxazin- und -thiazin-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP1262183A1 (en) * 1992-09-03 2002-12-04 Sepracor, Inc. Use of norastemizole for the treatment of allergic rhinitis
KR19990067622A (ko) * 1995-11-17 1999-08-25 게리 디. 스트리트, 스티븐 엘. 네스비트 알레르기성 질환의 치료에 유용한 치환된 4-(1h-벤즈이미다졸-2-일-아미노)피페리딘
PL191073B1 (pl) * 1996-08-16 2006-03-31 Schering Corp Zastosowanie kombinacji antagonistów receptorów histaminowych H1 i H3

Also Published As

Publication number Publication date
EP1035869A1 (en) 2000-09-20
AU6868098A (en) 1998-10-20
NO994655L (no) 1999-11-15
AR012187A1 (es) 2000-09-27
JP2002512614A (ja) 2002-04-23
HUP0001823A3 (en) 2002-04-29
CN1257431A (zh) 2000-06-21
RU2214245C2 (ru) 2003-10-20
AU735257B2 (en) 2001-07-05
NO994655D0 (no) 1999-09-24
NZ517472A (en) 2003-08-29
HUP0001823A2 (hu) 2001-04-28
KR20010005746A (ko) 2001-01-15
CA2284705A1 (en) 1998-10-01
ZA982562B (en) 1998-10-01
BR9808428A (pt) 2000-05-23
WO1998042379A3 (en) 2001-03-01
WO1998042379A2 (en) 1998-10-01
NZ527200A (en) 2004-12-24

Similar Documents

Publication Publication Date Title
BR9507917A (pt) Reagente para preparar um agente radiofarmacêutico agente formador de imagem processo para preparar o mesmo kit para preparar uma preparação farmacêutica uso do reagente agente radioterapêutico composição e agente radiofarmacêutico
ES2178943A1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
BG103518A (en) 2-(purin-9-yl)tetrahydrofuran-3,4-diol derivatives
NO944113L (no) Stabilt, hydratisert cefalosporin-tört pulver for oral suspensjonsformulering
CA2098302A1 (en) Medicaments
CZ258896A3 (en) Morpholine derivatives, process of their preparation and pharmaceutical compositions containing thereof
IL133623A0 (en) Antithrombotic agents
IL133627A0 (en) Antithrombotic agents
IL150895A0 (en) Oral, nasal and pulmonary formulations of copolymer-1
HUP0203870A2 (hu) Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény
CA2059263A1 (en) Composition comprising the (-) enantiomer of cis-4-amino-1-(2-hydromethyl-1,3-oxathiolan-5-yl)-(1h)-pyrimidine-2-one or an enriched composition thereof, and its uses as a pharmaceutical agent
CA2356380A1 (en) Immunosuppressive effects of pteridine derivatives
CA2188283A1 (en) Substituted 1,3-oxathiolanes with antiviral properties
BG103947A (en) Derivatives of 9-oxymerythromycin
EP0902789A4 (xx)
DE69925293D1 (de) Sprühbeschichtete mikropartikel für nadellose spritzen
CA2417935A1 (en) Anti-inflammatory medicament
NZ527201A (en) Stable norastemizole formulations comprising coated norastemizole particles
HUP0203226A2 (hu) Hatóanyagként benzamidszármazékot tartalmazó gyógyszerkészítmény
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
HRP20000704B1 (en) Controlled release peroral compositions of levosimendan
ES2145740T3 (es) Composiciones de factor de crecimiento, preparacion y uso.
NZ531813A (en) Pharmaceutical formulation
BG106093A (en) 14beta-h-sterols, pharmaceutical compositions comprising them and the use of these derivatives for the preparation of meiosis regulating medicaments
CA2089143A1 (en) Growth factor compositions, preparation and use

Legal Events

Date Code Title Description
PSEA Patent sealed